AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16020985 — intervention group
Group type: EXPERIMENTAL
Intervention: timely initiation of therapy within the first week following acoustic trauma
Number of subjects: 108
Study 16020985 — intervention group
Group type: EXPERIMENTAL
Intervention: degree of hearing improvement after medication
Number of subjects: 108
Study 11674925 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily for 4 weeks after a 2 week placebo period
Number of subjects: 31
Study 11674925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9476039 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg pyridostigmine
Number of subjects: 12
Study 9476039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7889958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil 20 mg/kg once daily
Number of subjects: 1597
Study 7889958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil twice daily
Number of subjects: 1597
Study 7889958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil once daily
Number of subjects: 1597
Study 7889958 — intervention group
Group type: COMPARATOR
Intervention: Penicillin three times a day
Number of subjects: 1597
Study 7889958 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor three times a day
Number of subjects: 1597
Study 7889958 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate four times a day
Number of subjects: 1597
Study 3312179 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 44
Study 3312179 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 44
Study 28815792 — intervention group
Group type: EXPERIMENTAL
Intervention: Farmed (legal) sea turtle products
Number of subjects: 560
Study 28815792 — intervention group
Group type: COMPARATOR
Intervention: Wild-sourced (illegal) sea turtle products
Number of subjects: 560
Study 28815792 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer preferences
Number of subjects: 560
Study 28815792 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice experiments
Number of subjects: 560
Study 27323347 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate 4 mg i.v. for 5 years, administered every 4 weeks for the first 6 months, every 3 months for the following 2 years, and every 6 months for the last 2.5 years.
Number of subjects: 0
Study 27323347 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 0
Study 27323347 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate
Number of subjects: 0
Study 25939514 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs5993891 in the ARVCF gene on chromosome 22q11
Number of subjects: 0
Study 25939514 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis across all studies
Number of subjects: 0
Study 24121220 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-electro-magnetic-regulation treatment
Number of subjects: 30
Study 24121220 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Bio-electro-magnetic-regulation treatment + Pentoxifylline infusions)
Number of subjects: 30
Study 24121220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21095135 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (CHO)
Number of subjects: 9
Study 21095135 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (PLA)
Number of subjects: 9
Study 18240145 — intervention group
Group type: EXPERIMENTAL
Intervention: HTI-286
Number of subjects: 0
Study 18240145 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous castration plus HTI-286 therapy
Number of subjects: 0
Study 16373903 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin analog
Number of subjects: 20
Study 16373903 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular insulin
Number of subjects: 20
Study 16373903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16373903 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study 14610014 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent atrial fibrillation (persistAF)
Number of subjects: 46
Study 14610014 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful cardioversion
Number of subjects: 46
Study 14610014 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct current (DC) energy
Number of subjects: 46
Study 14610014 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) levels
Number of subjects: 46
Study 14610014 — intervention group
Group type: EXPERIMENTAL
Intervention: HPCs from patients with AF
Number of subjects: 46
Study 11221123 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved STD case management using the syndromic approach at intervention health units.
Number of subjects: 8845
Study 11221123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention health units with improved STD services.
Number of subjects: 8845
Study 11221123 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits to non-returners after treatment.
Number of subjects: 8845
Study 11221123 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at intervention health units.
Number of subjects: 8845
Study 11221123 — intervention group
Group type: COMPARATOR
Intervention: Referral to higher levels of health care.
Number of subjects: 8845
Study 8817142 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuit with reduced systemic heparinization (ACT > 250 s) (n = 17)
Number of subjects: 33
Study 8817142 — intervention group
Group type: COMPARATOR
Intervention: Control group with uncoated circuits and full heparin dose (ACT > 480 s) (n = 16)
Number of subjects: 33
Study 1306211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (M1 muscarinic antagonist)
Number of subjects: 17
Study 1306211 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden (M1 muscarinic antagonist)
Number of subjects: 17
Study 1306211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3873478 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol, 0.5% (T)
Number of subjects: 36
Study 3873478 — intervention group
Group type: COMPARATOR
Intervention: Carteolol, 1% (C1)
Number of subjects: 36
Study 3873478 — intervention group
Group type: COMPARATOR
Intervention: Carteolol, 2% (C2)
Number of subjects: 36
Study 3873478 — intervention group
Group type: COMPARATOR
Intervention: Balanced saline (S)
Number of subjects: 36
Study 31661850 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A: 140 mg of ZynamiteÂ®, 140 mg of quercetin, 147.7 mg of maltodextrin, and 420 mg of sunflower lecithin
Number of subjects: 40
Study 31661850 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B: 140 mg of ZynamiteÂ®, 140 mg of quercetin, and 2126 mg of maltodextrin
Number of subjects: 40
Study 31661850 — intervention group
Group type: COMPARATOR
Intervention: Treatment C: 2548 mg of maltodextrin (placebo)
Number of subjects: 40
Study 31661850 — intervention group
Group type: EXPERIMENTAL
Intervention: ZynamiteÂ® with quercetin
Number of subjects: 40
Study 31661850 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenols (ZynamiteÂ® and quercetin)
Number of subjects: 40
Study 29808041 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid group (2gm of tranexamic acid diluted in 50ml of normal saline)
Number of subjects: 100
Study 29808041 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid group
Number of subjects: 100
Study 29808041 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (cardiac bath without tranexamic acid)
Number of subjects: 100
Study 26787023 — intervention group
Group type: EXPERIMENTAL
Intervention: Power whitening gel (38% Hydrogen Peroxide)
Number of subjects: 45
Study 26787023 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth whitening pen (16% Carbamide Peroxide)
Number of subjects: 45
Study 26787023 — intervention group
Group type: COMPARATOR
Intervention: Control group (artificial saliva)
Number of subjects: 45
Study 25146349 — intervention group
Group type: EXPERIMENTAL
Intervention: Danhong injection (DHI)
Number of subjects: 86
Study 25146349 — intervention group
Group type: COMPARATOR
Intervention: Non DHI group (control)
Number of subjects: 86
Study 22137765 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help strategies (26 strategies assessed)
Number of subjects: 1326
Study 19733931 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized chemotherapy based on ERCC1 mRNA expression for patients with low levels of ERCC1 (docetaxel/cisplatin) and high levels of ERCC1 (docetaxel/gemcitabine)
Number of subjects: 0
Study 19733931 — intervention group
Group type: EXPERIMENTAL
Intervention: CHRNA3 genotype (CT) in low genotypic group
Number of subjects: 0
Study 19733931 — intervention group
Group type: COMPARATOR
Intervention: Control arm received docetaxel/cisplatin
Number of subjects: 0
Study 18585496 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 3602
Study 18585496 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 3602
Study 18585496 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin plus routine use of GP IIb/IIIa inhibitors
Number of subjects: 3602
Study 18585496 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMSs)
Number of subjects: 3602
Study 17012684 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic psychotherapy with moderate level of transference interpretations
Number of subjects: 100
Study 17012684 — intervention group
Group type: COMPARATOR
Intervention: Dynamic psychotherapy with no transference interpretations
Number of subjects: 100
Study 14618108 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - micronized estradiol: 1 mg/day, progesterone: 0.25 mg/day
Number of subjects: 16
Study 14618108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11095120 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac-tobramycin combination
Number of subjects: 60
Study 11095120 — intervention group
Group type: COMPARATOR
Intervention: Fluorometholone-tobramycin combination
Number of subjects: 60
Study 8821085 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing from memory (with or without forewarning)
Number of subjects: 0
Study 8821085 — intervention group
Group type: COMPARATOR
Intervention: Copy condition
Number of subjects: 0
Study 8821085 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory conditions (drawing from memory)
Number of subjects: 0
Study 1467386 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (mCPP) 0.35 mg/kg
Number of subjects: 10
Study 1467386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6369214 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon
Number of subjects: 80
Study 6369214 — intervention group
Group type: COMPARATOR
Intervention: Balanced Salt Solution (BSS)
Number of subjects: 80
Study 31735969 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐paced weight loss intervention
Number of subjects: 204
Study 31735969 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor‐initiated weight loss intervention
Number of subjects: 204
Study 31735969 — intervention group
Group type: COMPARATOR
Intervention: Overall sample
Number of subjects: 204
Study 31735969 — intervention group
Group type: COMPARATOR
Intervention: Participants with overweight
Number of subjects: 204
Study 30240280 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% ASiR at normal dose (NI 10-40%)
Number of subjects: 40
Study 30240280 — intervention group
Group type: COMPARATOR
Intervention: 40% ASiR at low dose (NI 20-40%)
Number of subjects: 40
Study 30240280 — intervention group
Group type: EXPERIMENTAL
Intervention: MBIR at low dose (NI 20)
Number of subjects: 40
Study 30240280 — intervention group
Group type: EXPERIMENTAL
Intervention: MBIR
Number of subjects: 40
Study 27763682 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone (5, 15, and 30 mg)
Number of subjects: 12
Study 27763682 — intervention group
Group type: EXPERIMENTAL
Intervention: Opicapone (5, 15, and 50 mg)
Number of subjects: 12
Study 27763682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 26750622 — intervention group
Group type: EXPERIMENTAL
Intervention: ARNI (LCZ696; sacubitril-valsartan)
Number of subjects: 8000
Study 25074885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon ointment, 2 mL every 12 h for 10 days
Number of subjects: 144
Study 25074885 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment, 2 mL every 12 h for 10 days
Number of subjects: 144
Study 23211912 — intervention group
Group type: EXPERIMENTAL
Intervention: Wraparound video eyewear
Number of subjects: 128
Study 23211912 — intervention group
Group type: COMPARATOR
Intervention: Sunglasses (control)
Number of subjects: 128
Study 19530978 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 7
Study 19530978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 7
Study 19530978 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 7
Study 19530978 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 7
Study 19530978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 17517342 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum levels of apolipoprotein A-I (< 103 mg/dL)
Number of subjects: 117
Study 17517342 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of apolipoprotein A-I measured by immunoturbidimetry
Number of subjects: 117
Study 17517342 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical events during follow-up
Number of subjects: 117
Study 15133010 — intervention group
Group type: EXPERIMENTAL
Intervention: FI(O2) 0.10 (hypoxia)
Number of subjects: 6
Study 15133010 — intervention group
Group type: COMPARATOR
Intervention: FI(O2) 0.21 (normoxia)
Number of subjects: 6
Study 15133010 — intervention group
Group type: EXPERIMENTAL
Intervention: FI(O2) 1.00 (hyperoxia)
Number of subjects: 6
Study 15133010 — intervention group
Group type: EXPERIMENTAL
Intervention: End-exercise pH across treatments
Number of subjects: 6
Study 11868527 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent magnetic field (induction 60 mT) treatment
Number of subjects: 0
Study 9036306 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 3397
Study 9036306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3397
Study 7880762 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP)
Number of subjects: 38
Study 7880762 — intervention group
Group type: COMPARATOR
Intervention: 5-methoxypsoralen (5-MOP)
Number of subjects: 38
Study 3068633 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid combination
Number of subjects: 20
Study 3068633 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 20
Study 29576124 — intervention group
Group type: EXPERIMENTAL
Intervention: Median nerve block
Number of subjects: 12
Study 29576124 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar nerve block
Number of subjects: 12
Study 29576124 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial nerve block
Number of subjects: 12
Study 29576124 — intervention group
Group type: COMPARATOR
Intervention: All nerve blocks (median, ulnar, radial)
Number of subjects: 12
Study 28500678 — intervention group
Group type: EXPERIMENTAL
Intervention: BGG492 150 mg t.i.d.
Number of subjects: 93
Study 28500678 — intervention group
Group type: EXPERIMENTAL
Intervention: BGG492 100 mg t.i.d.
Number of subjects: 93
Study 28500678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 28500678 — intervention group
Group type: EXPERIMENTAL
Intervention: BGG492 (both doses) during open-label extension study
Number of subjects: 93
Study 28500678 — intervention group
Group type: EXPERIMENTAL
Intervention: BGG492 150 mg
Number of subjects: 93
Study 26290435 — intervention group
Group type: EXPERIMENTAL
Intervention: Blisibimod (0.1, 0.3, 1, or 3 mg/kg SC or 1, 3, or 6 mg/kg IV) - single dose
Number of subjects: 117
Study 26290435 — intervention group
Group type: EXPERIMENTAL
Intervention: Blisibimod (0.3, 1, or 3 mg/kg SC or 6 mg/kg IV) - four weekly doses
Number of subjects: 117
Study 26290435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 23104705 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth I (BI)
Number of subjects: 332
Study 23104705 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y (RY)
Number of subjects: 332
Study 22010227 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 agonist
Number of subjects: 36
Study 22010227 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 agonist
Number of subjects: 36
Study 22010227 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 receptor antagonist
Number of subjects: 36
Study 22010227 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 receptor antagonist
Number of subjects: 36
Study 22010227 — intervention group
Group type: COMPARATOR
Intervention: Saline controls
Number of subjects: 36
Study 19895679 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified CIMT
Number of subjects: 60
Study 19895679 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified BATRAC
Number of subjects: 60
Study 19895679 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment program (dose-matched)
Number of subjects: 60
Study 16484701 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 582
Study 16484701 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 582
Study 12827350 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (256 g per day)
Number of subjects: 0
Study 12827350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11034431 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Resistance (MR = 5.9 kg for females and 10.5 kg for males)
Number of subjects: 30
Study 11034431 — intervention group
Group type: COMPARATOR
Intervention: Light Resistance (LR = 1.4 kg for males and females)
Number of subjects: 30
Study 9012723 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 0
Study 8450998 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose apomorphine (0.01 mg/kg) SC
Number of subjects: 7
Study 8450998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3092934 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive female companions during labour
Number of subjects: 465
Study 3092934 — intervention group
Group type: COMPARATOR
Intervention: Labour alone
Number of subjects: 465
Study 31877910 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality exergame system (4 weeks, at least 2 extra sessions per week, average duration 44 min per session)
Number of subjects: 18
Study 31877910 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional therapy only)
Number of subjects: 18
Study 28157565 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Game Group (VGG) - exergames training delivered under variable practice schedule
Number of subjects: 111
Study 28157565 — intervention group
Group type: COMPARATOR
Intervention: Repetitive Game Group (RGG) - exergames training delivered under repetitive practice schedule
Number of subjects: 111
Study 25333245 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate (PN) 450 mg per day
Number of subjects: 13
Study 25333245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 13
Study 25333245 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate (PN)
Number of subjects: 13
Study 22945882 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMITAL®
Number of subjects: 30
Study 22945882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21877927 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise (EXE)
Number of subjects: 12
Study 21877927 — intervention group
Group type: COMPARATOR
Intervention: No physical exercise (CON)
Number of subjects: 12
Study 18457751 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intervention for 3 days a week for Group I
Number of subjects: 0
Study 18457751 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intervention for 5 days a week for Group II
Number of subjects: 0
Study 18457751 — intervention group
Group type: COMPARATOR
Intervention: Walking interventions (both groups)
Number of subjects: 0
Study 16705919 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical techniques for congenital heart diseases
Number of subjects: 0
Study 16705919 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up after heart surgery
Number of subjects: 0
Study 14700335 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite
Number of subjects: 30
Study 14700335 — intervention group
Group type: COMPARATOR
Intervention: Injectable resin modified glass ionomer
Number of subjects: 30
Study 14700335 — intervention group
Group type: COMPARATOR
Intervention: Compomer
Number of subjects: 30
Study 10960383 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 51
Study 10960383 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 51
Study 10960383 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 51
Study 10960383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapacuronium
Number of subjects: 51
Study 8792921 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) with Parietaria extract
Number of subjects: 25
Study 8792921 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 25
Study 8792921 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT)
Number of subjects: 25
Study 1599300 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon plus Carobel
Number of subjects: 50
Study 1599300 — intervention group
Group type: COMPARATOR
Intervention: Cisapride (0.8 mg/kg/day)
Number of subjects: 50
Study 6374058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 80
Study 6374058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 30317532 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (2000 pulses, 20 Hz at 100% rMT for 10 days)
Number of subjects: 26